🇺🇸 FDA
Patent

US 12030869

5-membered heteroaryl carboxamide compounds for treatment of HBV

granted A61PA61P31/12A61P31/20

Quick answer

US patent 12030869 (5-membered heteroaryl carboxamide compounds for treatment of HBV) held by ASSEMBLY BIOSCIENCES, INC. expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ASSEMBLY BIOSCIENCES, INC.
Grant date
Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61P, A61P31/12, A61P31/20